{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:05:47Z","timestamp":1758704747312,"version":"3.41.2"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>During the last two decades, two main schools of modern immunotherapy have come to the forefront. The chimeric anti-CD20 antibody rituximab that was introduced for the treatment of refractory follicular lymphoma in 1998 was one of the first examples of the school of passive immunotherapy. Subsequently major and ever more costly efforts were spent on the development of blockbuster monotherapies including other monoclonal but also bispecific antibodies of highly defined specificity and subclass, antibody\u2013drug conjugates (ADCs), as well as ex vivo expanded tumor-infiltrating lymphocytes, chimeric antigen receptor (CAR)-transduced T cells, and TCR-transduced T cells. On the other hand, there is the school that works toward active induction of patient B- or T-cell immunity against antigens of choice, or active tolerance against pathogenic allergens, auto-antigens or allo-antigens. Stradled in between these two approaches is treatment with blockers of T cell checkpoint control, which releases the brakes of T cells that have already responded to antigen. Extensive and detailed insight into the cellular and molecular interactions that regulate specific immune responses is indispensable in order to be able to optimize efficacy and rule out treatment related toxicity. This applies to all types of immunotherapy. Our knowledge of the checks and balances in the immune system is still increasing at an unprecedented pace, fostering ever more effective and specific (combination) immunotherapies and offering a rich harvest of innovative immunotherapies in the years ahead.<\/jats:p>","DOI":"10.1093\/immadv\/ltaa005","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T08:45:30Z","timestamp":1606293930000},"source":"Crossref","is-referenced-by-count":8,"title":["Special Review: The future of Immunotherapy"],"prefix":"10.1093","volume":"1","author":[{"given":"Cornelis J M","family":"Melief","sequence":"first","affiliation":[{"name":"Department of Immunology, Leiden University Medical Center , Leiden, Netherlands"},{"name":"ISA Pharmaceuticals , Leiden, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"issue":"24","key":"2023020702314376800_CIT0001","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"New Engl J Med"},{"issue":"28","key":"2023020702314376800_CIT0002","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1073\/pnas.1510830112","article-title":"Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection","volume":"112","author":"Pascal","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2023020702314376800_CIT0003","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J Clin Invest"},{"key":"2023020702314376800_CIT0004","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: overcoming the challenges posed by immune evasion","volume":"16","author":"Van der Burg","year":"2016","journal-title":"Nature Rev Cancer"},{"key":"2023020702314376800_CIT0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"key":"2023020702314376800_CIT0006","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2023020702314376800_CIT0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/asheducation-2018.1.9","article-title":"Antibody-based therapies in patients with acute lymphoblastic leukemia","author":"Dinner","year":"2018","journal-title":"Hematology"},{"key":"2023020702314376800_CIT0008","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","article-title":"Frontline treatment of acute myeloid leukemia in adults","volume":"110","author":"Tamamyan","year":"2017","journal-title":"Crit Rev Onc\/Hemat"},{"issue":"7","key":"2023020702314376800_CIT0009","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual HER2-positive breast cancer","volume":"380","author":"Von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2023020702314376800_CIT0010","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ymthe.2017.03.034","article-title":"Chimeric antigen receptors: a cell and gene therapy perspective","volume":"25","author":"Riviere","year":"2017","journal-title":"Molecular Therapy"},{"issue":"4","key":"2023020702314376800_CIT0011","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","article-title":"Cytokine release syndrome: who is at risk and how to treat","volume":"30","author":"Frey","year":"2017","journal-title":"Best practice & research clin Hemat"},{"issue":"26","key":"2023020702314376800_CIT0012","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant negative TGF \u03b2 Receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Molecular Therapy"},{"issue":"2","key":"2023020702314376800_CIT0013","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2015","journal-title":"Cancer discovery"},{"key":"2023020702314376800_CIT0014","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20 anti-CD-19 CAR T cells for relapsed B cell malignancies. A phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"2023020702314376800_CIT0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.soc.2019.02.012","article-title":"Adoptive T cell therapy for solid malignancies","volume":"28","author":"Jafferji","year":"2019","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"2023020702314376800_CIT0016","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1158\/2326-6066.CIR-18-0888","article-title":"Adoptive immunotherapy with antigen-specific T cells expressing a native TCR","volume":"7","author":"Leung","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"2023020702314376800_CIT0017","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2023020702314376800_CIT0018","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/107327481302000406","article-title":"Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy","volume":"20","author":"Phan","year":"2013","journal-title":"Cancer Control"},{"issue":"19","key":"2023020702314376800_CIT0019","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"New Engl J of Med"},{"issue":"10","key":"2023020702314376800_CIT0020","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-15-2594","article-title":"Vaccination against oncoproteins of HPV16 for noninvasive vulvar\/ vaginal lesions: lesion clearance is related to the strength of the T cell response","volume":"22","author":"Van Poelgeest","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"2023020702314376800_CIT0021","first-page":"1","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2017","journal-title":"Nat Comm"},{"key":"2023020702314376800_CIT0022","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine against HPV16\/18 E6 & E7 proteins for CIN2\/3: a randomized double blind, placebo-controlled trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2023020702314376800_CIT0023","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable HPV16- related cancer. A phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023020702314376800_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaz8235","article-title":"Strong vaccine responses during chemotherapy are associated with prolonged cancer survival","volume":"12","author":"Melief","year":"2020","journal-title":"Science Transl Med"},{"issue":"8","key":"2023020702314376800_CIT0025","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-10-2888","article-title":"Local activation of CD8+ T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody","volume":"17","author":"Fransen","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2023020702314376800_CIT0026","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-12-0781","article-title":"Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T cell dependent tumor eradication and decreases risk of toxic side effects","volume":"19","author":"Fransen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"45","key":"2023020702314376800_CIT0027","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"journal-title":"Nature Rev Cancer","article-title":"The promise of therapeutic cancer vaccines","author":"Saxena","key":"2023020702314376800_CIT0028"},{"key":"2023020702314376800_CIT0029","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"2023020702314376800_CIT0030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"3","key":"2023020702314376800_CIT0031","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14712598.2020.1714027","article-title":"Anti-IL-4\/ IL-13 for the treatment of asthma: the story so far","volume":"20","author":"Moran","year":"2020","journal-title":"Expert Opin On Biol Ther"},{"issue":"5","key":"2023020702314376800_CIT0032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11894-018-0624-y","article-title":"Food Allergy. Curr","volume":"20","author":"Iweala","year":"2018","journal-title":"Gastroenterol Rep"},{"issue":"3","key":"2023020702314376800_CIT0033","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jaci.2018.03.023","article-title":"Induction of bystander tolerance and immune deviation after Fel d1 peptide immunotherapy","volume":"143","author":"Moldaver","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2023020702314376800_CIT0034","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaci.2016.11.043","article-title":"Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis","volume":"140","author":"Ellis","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2023020702314376800_CIT0035","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJMra1911109","article-title":"Tolerance in the age of immunotherapy","volume":"383","author":"Bluestone","year":"2020","journal-title":"New Engl J Med"},{"issue":"12","key":"2023020702314376800_CIT0036","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/lt.24845","article-title":"Tolerance after liver transplantation: where are we?","volume":"23","author":"Feng","year":"2017","journal-title":"Liver Transpl"},{"issue":"10","key":"2023020702314376800_CIT0037","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/tri.13504","article-title":"Tolerogenic dendritic cells in organ transplantation","volume":"33","author":"Ochando","year":"2020","journal-title":"Transplant International"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/immunotherapyadv\/advance-article-pdf\/doi\/10.1093\/immadv\/ltaa005\/34478315\/ltaa005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/1\/1\/ltaa005\/49106211\/ltaa005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/1\/1\/ltaa005\/49106211\/ltaa005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T02:32:19Z","timestamp":1675737139000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltaa005\/5999882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltaa005","relation":{},"ISSN":["2732-4303"],"issn-type":[{"type":"electronic","value":"2732-4303"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,11,25]]},"article-number":"ltaa005"}}